Work

Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives

Year: 2026
Type: article
Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains characterized by aggressive progression, extensive stromal remodeling, early metastatic dissemination, and resistance to systemic therapy. Nuclear factor kappa B (NF-κB) integrates oncogenic, inflammatory, survival, angiogenic, and treatment-induced signals and therefore represents a pharmacologically relevant regulatory node in pancreatic cancer. Phytochemicals including curcumin, xanthohumol, parthenolide, dimethylaminoparthenolide, triptolide, resveratrol, emodin, and related compounds have been investigated as modulators of NF-κB activity, although the strength of mechanistic evidence differs substantially among agents. This review evaluates canonical and noncanonical NF-κB biology in pancreatic cancer, interactions with KRAS, PI3K-AKT, STAT3, MAPK, and Nrf2 signaling, and the consequences of NF-κB modulation for apoptosis, epithelial–mesenchymal transition, angiogenesis, tumor microenvironmental communication, and chemotherapy resistance. Particular emphasis is placed on separating direct pharmacodynamic evidence from downstream pathway association and computational prediction. Curcumin and xanthohumol have been evaluated using direct NF-κB measurements linked to defined antitumor phenotypes and in vivo validation, whereas parthenolide and dimethylaminoparthenolide support a mechanistic relationship between NF-κB activity and gemcitabine resistance. Clinical evidence remains limited and is dominated by early phase curcumin studies, which also illustrate major barriers involving bioavailability, tumor exposure, and target engagement. Future development requires exposure–response analysis, cell-type-specific pharmacodynamics, rational combination therapy, validated biomarkers, and formulations or derivatives with improved pharmacokinetic properties. An evidence-based pharmacological framework may clarify which phytochemical NF-κB modulators warrant further translational development and biomarker-guided evaluation in PDAC.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7234764092
FWCI:
Cites: 70
Cited by:
Related to: 10